Cargando…

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study

BACKGROUND: Gram-negative bacteria mediated gemcitabine resistance in pre-clinical models. We determined if intratumoural lipopolysaccharide (LPS) detection by immunohistochemistry is associated with outcome in advanced pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine and non-gemcita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guenther, Michael, Haas, Michael, Heinemann, Volker, Kruger, Stephan, Westphalen, Christoph Benedikt, von Bergwelt-Baildon, Michael, Mayerle, Julia, Werner, Jens, Kirchner, Thomas, Boeck, Stefan, Ormanns, Steffen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591915/ https://www.ncbi.nlm.nih.gov/pubmed/32830200 http://dx.doi.org/10.1038/s41416-020-01029-7

Ejemplares similares

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer
por: Guenther, Michael, et al.
Publicado: (2022)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
por: Ormanns, Steffen, et al.
Publicado: (2014)

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
por: Guenther, Michael, et al.
Publicado: (2023)

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
por: Boeck, S, et al.
Publicado: (2013)

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Sams, L., et al.
Publicado: (2021)

Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers
por: Dorman, Klara, et al.
Publicado: (2022)

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy
por: Ormanns, Steffen, et al.
Publicado: (2017)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
por: Kruger, S.F., et al.
Publicado: (2022)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2019)

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
por: Stintzing, S, et al.
Publicado: (2011)

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research
por: Baechmann, Sibylle, et al.
Publicado: (2017)

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board
por: Dorman, Klara, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult
por: Boeck, S, et al.
Publicado: (2014)

Advances in cancer immunotherapy 2019 – latest trends
por: Kruger, Stephan, et al.
Publicado: (2019)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich
por: Zhang, Danmei, et al.
Publicado: (2023)

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer
por: Haas, Michael, et al.
Publicado: (2017)

Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
por: Weiss, L., et al.
Publicado: (2023)

Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy
por: von Baumgarten, Louisa, et al.
Publicado: (2020)

Aios in coronatijd
por: Maria Greijn, Claudia, et al.
Publicado: (2020)

Implementing precision oncology for sarcoma patients: the CCC(LMU)molecular tumor board experience
por: Berclaz, Luc M., et al.
Publicado: (2023)

DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
por: Ettrich, Thomas J., et al.
Publicado: (2016)

Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh(®TM)) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
por: Dorman, Klara, et al.
Publicado: (2023)

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
por: Ettrich, Thomas J., et al.
Publicado: (2018)

Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting
por: Sultova, Elena, et al.
Publicado: (2021)

OA01.04. The effectiveness and cost effectiveness of acupressure for chemotherapy-related nausea
por: Hughes, J, et al.
Publicado: (2012)

AIOS proceedings: A response
por: Rajendran, Babu
Publicado: (2009)

19. AIO-Herbstkongress 2022
Publicado: (2023)

NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU
por: Sultova, Elena, et al.
Publicado: (2020)

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
por: Heinemann, Volker, et al.
Publicado: (2008)

Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030
por: Quante, Anne S., et al.
Publicado: (2016)

Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy
por: Heinrich, Kathrin, et al.
Publicado: (2023)

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study
por: Westphalen, C. Benedikt, et al.
Publicado: (2020)

PA01.04. Clinical study of shvadmstradi kwatha in the management of mutra ashmari (urinary calculi)
por: Thameem, Mohammed
Publicado: (2013)

PA01.04. Assessment of acharrasayan in domain of physical, mental & social health in Ayurveda students
por: Desai, Priti, et al.
Publicado: (2012)

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

OA01.04. Ayurvedic management of chronic rheumatoid arthritis with severe deformities - A case report
por: Sujithra, RM, et al.
Publicado: (2013)

P01.04. Learning From Within: Peer-based Group Coaching Among Undergraduate Students
por: Sommers, Jayne, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c65vc0esfg6qsf8d77bhj4jrg0